Comparing two after-surgery chemo options for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding two chemotherapy drugs (cisplatin and gemcitabine) after surgery works better than the usual pill (capecitabine) for people with triple-negative breast cancer that did not fully respond to initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have triple-negative breast cancer (no hormone receptors or HER2).
- Your cancer had not spread to distant parts of the body before starting treatment.
- You already had standard chemotherapy before surgery, but it did not completely eliminate all cancer cells.
- You are generally active and able to do daily tasks (performance status 0 or 1).
- Your blood tests show your liver, kidneys, and blood cells are healthy enough for more chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.